Morgan Stanley Corvus Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 397,364 shares of CRVS stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

397,364

Previous 393,262 1.04%

Holding current value

$1.61 Million

Previous $2.08 Million 0.48%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.55 - $9.56 $18,664 - $39,215	4,102 Added 1.04%	397,364 $2.07 Million
Q3 2024 Nov 14, 2024	BUY	$1.78 - $5.92 $38,909 - $129,405	21,859 Added 5.89%	393,262 $2.08 Million
Q2 2024 Oct 17, 2024	BUY	$1.36 - $2.29 $130,617 - $219,936	96,042 Added 34.88%	371,403 $675,000
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.29 $130,617 - $219,936	96,042 Added 34.88%	371,403 $675,000
Q1 2024 Oct 17, 2024	SELL	$1.76 - $2.41 $169,033 - $231,461	-96,042 Reduced 25.86%	275,361 $490,000
Q1 2024 Aug 16, 2024	BUY	$1.76 - $2.41 $27,642 - $37,851	15,706 Added 6.05%	275,361 $490,000
Q1 2024 May 15, 2024	BUY	$1.76 - $2.41 $27,642 - $37,851	15,706 Added 6.05%	275,361 $490,000
Q4 2023 Aug 16, 2024	SELL	$1.08 - $1.92 $120,687 - $214,556	-111,748 Reduced 30.09%	259,655 $456,000
Q4 2023 Feb 13, 2024	BUY	$1.08 - $1.92 $72,520 - $128,926	67,149 Added 34.88%	259,655 $456,000
Q3 2023 Nov 15, 2023	BUY	$1.41 - $2.97 $74,548 - $157,026	52,871 Added 37.86%	192,506 $281,000
Q2 2023 Aug 14, 2023	BUY	$1.0 - $3.86 $39,476 - $152,377	39,476 Added 39.41%	139,635 $319,000
Q1 2023 May 15, 2023	BUY	$0.65 - $0.92 $17,910 - $25,349	27,554 Added 37.95%	100,159 $91,000
Q4 2022 Feb 14, 2023	BUY	$0.74 - $1.04 $24,633 - $34,619	33,288 Added 84.67%	72,605 $61,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $1.17 $7,122 - $11,736	-10,031 Reduced 20.33%	39,317 $32,000
Q2 2022 Oct 27, 2022	BUY	$0.87 - $2.03 $7,382 - $17,226	8,486 Added 20.77%	49,348 $49,000
Q2 2022 Aug 15, 2022	BUY	$0.87 - $2.03 $7,382 - $17,226	8,486 Added 20.77%	49,348 $49,000
Q1 2022 Oct 27, 2022	SELL	$1.46 - $2.48 $12,389 - $21,045	-8,486 Reduced 17.2%	40,862 $67,000
Q1 2022 May 13, 2022	BUY	$1.46 - $2.48 $5,819 - $9,885	3,986 Added 10.81%	40,862 $67,000
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $16,223 - $36,814	6,933 Added 23.15%	36,876 $88,000
Q3 2021 Nov 15, 2021	BUY	$1.89 - $8.53 $56,592 - $255,413	29,943 New	29,943 $145,000

Others Institutions Holding CRVS

# of Institutions

102

Shares Held

38.1M

Call Options Held

2.75M

Put Options Held

1.17M

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $188M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account